. Department, I. Haematology, . Ospedale-san-martino, and I. Genoa, 12 Bone Marrow Transplantation Department Anadolu Medical Center Hospital, Kocaeli, Turkey. 13 Department of Hematology, Stem Cell Transplant Unit, Medical Park Hospitals Hematology Division, issue.11, 2019.

P. Beatty, R. Clift, E. Mickelson, B. Nisperos, N. Flournoy et al., Marrow Transplantation from Related Donors Other Than HLA-Identical Siblings, New England Journal of Medicine, vol.313, issue.13, pp.765-71, 1985.
DOI : 10.1056/NEJM198509263131301

C. Anasetti, D. Amos, P. Beatty, F. Appelbaum, W. Bensinger et al., Effect of HLA Compatibility on Engraftment of Bone Marrow Transplants in Patients with Leukemia or Lymphoma, New England Journal of Medicine, vol.320, issue.4, pp.197-204, 1989.
DOI : 10.1056/NEJM198901263200401

C. Anasetti, P. Beatty, R. Storb, P. Martin, M. Mori et al., Effect of HLA incompatibility on graft-versus-host disease, relapse, and survival after marrow transplantation for patients with leukemia or lymphoma, Human Immunology, vol.29, issue.2, pp.79-91, 1990.
DOI : 10.1016/0198-8859(90)90071-V

Y. Kanda, S. Chiba, H. Hirai, H. Sakamaki, T. Iseki et al., Allogeneic hematopoietic stem cell transplantation from family members other than HLA-identical siblings over the last decade (1991-2000), Blood, vol.102, issue.4, pp.1541-1548, 1991.
DOI : 10.1182/blood-2003-02-0430

F. Aversa, A. Tabilio, A. Velardi, I. Cunningham, A. Terenzi et al., Treatment of High-Risk Acute Leukemia with T-Cell???Depleted Stem Cells from Related Donors with One Fully Mismatched HLA Haplotype, New England Journal of Medicine, vol.339, issue.17, pp.1186-93, 1998.
DOI : 10.1056/NEJM199810223391702

J. Mehta, S. Singhal, A. Gee, K. Chiang, K. Godder et al., Bone marrow transplantation from partially HLA-mismatched family donors for acute leukemia: single-center experience of 201 patients, Bone Marrow Transplantation, vol.33, issue.4, pp.389-96, 2004.
DOI : 10.1038/sj.bmt.1704391

P. Lang, J. Greil, P. Bader, R. Handgretinger, T. Klingebiel et al., Long-term outcome after haploidentical stem cell transplantation in children, Blood Cells, Molecules, and Diseases, vol.33, issue.3, pp.281-288, 2004.
DOI : 10.1016/j.bcmd.2004.08.017

E. Waller, C. Giver, H. Rosenthal, J. Somani, A. Langston et al., Facilitating T-cell immune reconstitution after haploidentical transplantation in adults, Blood Cells, Molecules, and Diseases, vol.33, issue.3, pp.233-240, 2004.
DOI : 10.1016/j.bcmd.2004.08.009

F. Aversa, A. Terenzi, A. Tabilio, F. Falzetti, A. Carotti et al., Full Haplotype-Mismatched Hematopoietic Stem-Cell Transplantation: A Phase II Study in Patients With Acute Leukemia at High Risk of Relapse, Journal of Clinical Oncology, vol.23, issue.15, pp.3447-54, 2005.
DOI : 10.1200/JCO.2005.09.117

F. Aversa, T cell depleted haploidentical transplantation: positive selection. Pediatric reports, p.14, 2011.

X. Huang, D. Liu, K. Liu, L. Xu, H. Chen et al., Treatment of Acute Leukemia with Unmanipulated HLA-Mismatched/Haploidentical Blood and Bone Marrow Transplantation, Biology of Blood and Marrow Transplantation, vol.15, issue.2, pp.257-65, 2009.
DOI : 10.1016/j.bbmt.2008.11.025

Y. Wang, D. Liu, K. Liu, L. Xu, X. Zhang et al., Long-term follow-up of haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for the treatment of leukemia, Cancer, vol.17, issue.5, pp.978-85, 2013.
DOI : 10.1002/cncr.27761

K. Lee, J. Lee, J. Lee, D. Kim, M. Seol et al., Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome, Blood, vol.118, issue.9, pp.2609-2626, 2011.
DOI : 10.1182/blood-2011-02-339838

D. Bartolomeo, P. Santarone, S. , D. Angelis, G. Picardi et al., Haploidentical, unmanipulated, G-CSF-primed bone marrow transplantation for patients with high-risk hematologic malignancies, Blood, vol.121, issue.5, pp.849-57, 2013.
DOI : 10.1182/blood-2012-08-453399

W. Arcese, A. Picardi, S. Santarone, D. Angelis, G. Cerretti et al., Haploidentical, G-CSF-primed, unmanipulated bone marrow transplantation for patients with high-risk hematological malignancies: an update, Bone Marrow Transplantation, vol.49, issue.2, pp.24-30, 2015.
DOI : 10.1016/j.bbmt.2013.11.020

J. Peccatori, A. Forcina, D. Clerici, R. Crocchiolo, L. Vago et al., Sirolimus-based graft-versus-host disease prophylaxis promotes the in vivo expansion of regulatory T cells and permits peripheral blood stem cell transplantation from haploidentical donors, Leukemia, vol.707, issue.2, pp.396-405, 2015.
DOI : 10.1182/blood-2013-08-519413

L. Luznik, O. Donnell, P. Symons, H. Chen, A. Leffell et al., HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide, Biology of Blood and Marrow Transplantation, vol.14, issue.6, pp.641-50, 2008.
DOI : 10.1016/j.bbmt.2008.03.005

Y. Kasamon, L. Luznik, M. Leffell, J. Kowalski, H. Tsai et al., Nonmyeloablative HLA-Haploidentical Bone Marrow Transplantation with High-Dose Posttransplantation Cyclophosphamide: Effect of HLA Disparity on Outcome, Biology of Blood and Marrow Transplantation, vol.16, issue.4, pp.482-491, 2010.
DOI : 10.1016/j.bbmt.2009.11.011

A. Munchel, Y. Kasamon, and E. Fuchs, Treatment of hematological malignancies with nonmyeloablative, HLA-haploidentical bone marrow transplantation and high dose, post-transplantation cyclophosphamide, Best Practice & Research Clinical Haematology, vol.24, issue.3, pp.359-68, 2011.
DOI : 10.1016/j.beha.2011.05.001

S. Ciurea, V. Mulanovich, R. Saliba, U. Bayraktar, Y. Jiang et al., Improved Early Outcomes Using a T Cell Replete Graft Compared with T Cell Depleted Haploidentical Hematopoietic Stem Cell Transplantation, Biology of Blood and Marrow Transplantation, vol.18, issue.12, pp.1835-1879, 2012.
DOI : 10.1016/j.bbmt.2012.07.003

S. Solomon, C. Sizemore, M. Sanacore, X. Zhang, S. Brown et al., Haploidentical Transplantation Using T Cell Replete Peripheral Blood Stem Cells and Myeloablative Conditioning in Patients with High-Risk Hematologic Malignancies Who Lack Conventional Donors is Well Tolerated and Produces Excellent Relapse-Free Survival: Results of a Prospective Phase II Trial, Biology of Blood and Marrow Transplantation, vol.18, issue.12, pp.1859-66, 2012.
DOI : 10.1016/j.bbmt.2012.06.019

A. Raiola, A. Dominietto, A. Ghiso, D. Grazia, C. Lamparelli et al., Unmanipulated Haploidentical Bone Marrow Transplantation and Posttransplantation Cyclophosphamide for Hematologic Malignancies after Myeloablative Conditioning, Biology of Blood and Marrow Transplantation, vol.19, issue.1, pp.117-139, 2013.
DOI : 10.1016/j.bbmt.2012.08.014

A. Raiola, A. Dominietto, R. Varaldo, A. Ghiso, F. Galaverna et al., Unmanipulated haploidentical BMT following non-myeloablative conditioning and post-transplantation CY for advanced Hodgkin???s lymphoma, Bone Marrow Transplantation, vol.17, issue.2, pp.190-194, 2014.
DOI : 10.1111/j.1365-2141.2010.08492.x

A. Bacigalupo, A. Dominietto, A. Ghiso, D. Grazia, C. Lamparelli et al., Unmanipulated haploidentical bone marrow transplantation and post-transplant cyclophosphamide for hematologic malignanices following a myeloablative conditioning: an update, Bone Marrow Transplantation, vol.50, issue.2, pp.37-46, 2015.
DOI : 10.1016/j.bbmt.2012.08.014

N. Cieri, R. Greco, L. Crucitti, M. Morelli, F. Giglio et al., Post-transplantation Cyclophosphamide and Sirolimus after Haploidentical Hematopoietic Stem Cell Transplantation Using a Treosulfan-based Myeloablative Conditioning and Peripheral Blood Stem Cells, Biology of Blood and Marrow Transplantation, vol.21, issue.8, pp.1506-1520, 2015.
DOI : 10.1016/j.bbmt.2015.04.025

L. Castagna, S. Bramanti, S. Furst, L. Giordano, R. Crocchiolo et al., Nonmyeloablative conditioning, unmanipulated haploidentical SCT and post-infusion CY for advanced lymphomas, Bone Marrow Transplantation, vol.14, issue.12, pp.1475-80, 2014.
DOI : 10.1038/bmt.2014.197

J. Tischer, N. Engel, S. Fritsch, D. Prevalsek, M. Hubmann et al., Virus infection in HLA-haploidentical hematopoietic stem cell transplantation: incidence in the context of immune recovery in two different transplantation settings, Annals of Hematology, vol.20, issue.8, pp.1677-88, 2015.
DOI : 10.1007/s00277-015-2423-y

Y. Chang, X. Zhao, and X. Huang, Immune Reconstitution after Haploidentical Hematopoietic Stem Cell Transplantation, Biology of Blood and Marrow Transplantation, vol.20, issue.4, pp.440-449, 2014.
DOI : 10.1016/j.bbmt.2013.11.028

M. Shabbir-moosajee, L. Lombardi, and S. Ciurea, An overview of conditioning regimens for haploidentical stem cell transplantation with post-transplantation cyclophosphamide, American Journal of Hematology, vol.20, issue.6, pp.541-549, 2015.
DOI : 10.1002/ajh.23995

J. Kanakry, Y. Kasamon, C. Gocke, H. Tsai, J. Davis-sproul et al., Outcomes of Related Donor HLA-Identical or HLA-Haploidentical Allogeneic Blood or Marrow Transplantation for Peripheral T Cell Lymphoma, Biology of Blood and Marrow Transplantation, vol.19, issue.4, pp.602-608, 2013.
DOI : 10.1016/j.bbmt.2013.01.006

D. Stasi, A. Milton, D. Poon, L. Hamdi, A. Rondon et al., Similar Transplantation Outcomes for Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients with Haploidentical versus 10/10 Human Leukocyte Antigen???Matched Unrelated and Related Donors, Biology of Blood and Marrow Transplantation, vol.20, issue.12, pp.1975-81, 2014.
DOI : 10.1016/j.bbmt.2014.08.013

A. Raiola, A. Dominietto, C. Di-grazia, T. Lamparelli, F. Gualandi et al., Unmanipulated Haploidentical Transplants Compared with Other Alternative Donors and Matched Sibling Grafts, Biology of Blood and Marrow Transplantation, vol.20, issue.10, pp.1573-1582, 2014.
DOI : 10.1016/j.bbmt.2014.05.029

D. Blaise, S. Furst, R. Crocchiolo, J. El-cheikh, A. Granata et al., Haploidentical T Cell???Replete Transplantation with Post-Transplantation Cyclophosphamide for Patients in or above the Sixth Decade of Age Compared with Allogeneic Hematopoietic Stem Cell Transplantation from an Human Leukocyte Antigen???Matched Related or Unrelated Donor, Biology of Blood and Marrow Transplantation, vol.22, issue.1, pp.119-143, 2016.
DOI : 10.1016/j.bbmt.2015.08.029

A. Bashey, X. Zhang, C. Sizemore, K. Manion, S. Brown et al., T-Cell???Replete HLA-Haploidentical Hematopoietic Transplantation for Hematologic Malignancies Using Post-Transplantation Cyclophosphamide Results in Outcomes Equivalent to Those of Contemporaneous HLA-Matched Related and Unrelated Donor Transplantation, Journal of Clinical Oncology, vol.31, issue.10, pp.311310-311316, 2013.
DOI : 10.1200/JCO.2012.44.3523

S. Ciurea, M. Zhang, A. Bacigalupo, A. Bashey, F. Appelbaum et al., Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia, Blood, vol.126, issue.8, pp.1033-1073, 2015.
DOI : 10.1182/blood-2015-04-639831

S. Solomon, C. Sizemore, M. Sanacore, X. Zhang, S. Brown et al., Total Body Irradiation???Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation in Patients Without Matched Sibling Donors, Biology of Blood and Marrow Transplantation, vol.21, issue.7, pp.1299-307, 2015.
DOI : 10.1016/j.bbmt.2015.03.003

A. Bashey, X. Zhang, K. Jackson, S. Brown, M. Ridgeway et al., Comparison of Outcomes of Hematopoietic Cell Transplants??from T-Replete Haploidentical Donors Using Post-Transplantation Cyclophosphamide with 10 of 10 HLA-A,??-B, -C, -DRB1, and -DQB1 Allele-Matched Unrelated Donors and HLA-Identical Sibling Donors: A Multivariable Analysis Including Disease Risk Index, Biology of Blood and Marrow Transplantation, vol.22, issue.1, pp.125-158, 2016.
DOI : 10.1016/j.bbmt.2015.09.002

A. Shimoni, I. Hardan, N. Shem-tov, M. Yeshurun, R. Yerushalmi et al., Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity, Leukemia, vol.19, issue.2, pp.322-330, 2006.
DOI : 10.1038/sj.leu.2404037

M. De-lima, A. Anagnostopoulos, M. Munsell, M. Shahjahan, N. Ueno et al., Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation, Blood, vol.104, issue.3, pp.865-72, 2004.
DOI : 10.1182/blood-2003-11-3750

J. Magenau, T. Braun, P. Reddy, B. Parkin, A. Pawarode et al., Allogeneic transplantation with myeloablative FluBu4 conditioning improves survival compared to reduced intensity FluBu2 conditioning for acute myeloid leukemia in remission, Annals of Hematology, vol.23, issue.24, pp.1033-1074, 2015.
DOI : 10.1007/s00277-015-2349-4

M. Mohty, M. Labopin, L. Volin, A. Gratwohl, G. Socie et al., Reduced-intensity versus conventional myeloablative conditioning allogeneic stem cell transplantation for patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation, Blood, vol.116, issue.22, pp.4439-4482, 2010.
DOI : 10.1182/blood-2010-02-266551

D. Marks, T. Wang, W. Perez, J. Antin, E. Copelan et al., The outcome of full-intensity and reduced-intensity conditioning matched sibling or unrelated donor transplantation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first and second complete remission, Blood, vol.116, issue.3, pp.366-74, 2010.
DOI : 10.1182/blood-2010-01-264077

M. Aoudjhane, M. Labopin, N. Gorin, A. Shimoni, T. Ruutu et al., Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT), Leukemia, vol.18, issue.12, pp.2304-2316, 2005.
DOI : 10.1016/S0140-6736(00)02137-1

V. Bachanova, D. Marks, M. Zhang, H. Wang, M. De-lima et al., Ph+ ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplantation: impact of tyrosine kinase inhibitor and minimal residual disease, Leukemia, vol.27, issue.3, pp.658-65, 2014.
DOI : 10.1038/leu.2013.253
URL : https://hal.archives-ouvertes.fr/hal-00979461

O. Ringden, M. Labopin, G. Ehninger, D. Niederwieser, R. Olsson et al., Reduced Intensity Conditioning Compared With Myeloablative Conditioning Using Unrelated Donor Transplants in Patients With Acute Myeloid Leukemia, Journal of Clinical Oncology, vol.27, issue.27, pp.4570-4577, 2009.
DOI : 10.1200/JCO.2008.20.9692

M. Sebert, R. Porcher, R. M. Ades, L. Boissel, N. Raffoux et al., Equivalent outcomes using reduced intensity or conventional myeloablative conditioning transplantation for patients aged 35 years and over with AML, Bone Marrow Transplantation, vol.120, issue.1, 2014.
DOI : 10.1182/blood-2011-05-352989

A. Wahid, S. Ismail, N. Mohd-idris, M. Jamaluddin, F. Tumian et al., Comparison of Reduced-Intensity and Myeloablative Conditioning Regimens for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia: A Meta-Analysis, Stem Cells and Development, vol.23, issue.21, pp.2535-52, 2014.
DOI : 10.1089/scd.2014.0123

M. Bornhauser, J. Kienast, R. Trenschel, A. Burchert, U. Hegenbart et al., Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial, The Lancet Oncology, vol.13, issue.10, pp.1035-1079, 2012.
DOI : 10.1016/S1470-2045(12)70349-2

S. Mccurdy, J. Kanakry, M. Showel, H. Tsai, J. Bolanos-meade et al., Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide, Blood, vol.125, issue.19, pp.3024-3055, 2015.
DOI : 10.1182/blood-2015-01-623991

V. Bachanova and D. Weisdorf, Unrelated donor allogeneic transplantation for adult acute lymphoblastic leukemia: a review, Bone Marrow Transplantation, vol.100, issue.5, pp.455-64, 2008.
DOI : 10.1038/sj.bmt.1704091

X. Huang, D. Liu, K. Liu, L. Xu, H. Chen et al., Haploidentical Hematopoietic Stem Cell Transplantation without In Vitro T Cell Depletion for Treatment of Hematologic Malignancies in Children, Biology of Blood and Marrow Transplantation, vol.15, issue.1, pp.91-95, 2009.
DOI : 10.1016/j.bbmt.2008.10.019

A. Nagler, M. Labopin, A. Shimoni, D. Niederwieser, G. Mufti et al., Mobilized Peripheral Blood Stem Cells Compared with Bone Marrow as the Stem Cell Source for Unrelated Donor Allogeneic Transplantation with Reduced-Intensity Conditioning in Patients with Acute Myeloid Leukemia in Complete Remission: An Analysis from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation, Biology of Blood and Marrow Transplantation, vol.18, issue.9, pp.1422-1431, 2012.
DOI : 10.1016/j.bbmt.2012.02.013

D. Gallardo, R. De-la-camara, J. Nieto, I. Espigado, A. Iriondo et al., Is mobilized peripheral blood comparable with bone marrow as a source of hematopoietic stem cells for allogeneic transplantation from HLA-identical sibling donors? A case-control study, Haematologica, vol.94, issue.9, pp.1282-1290, 2009.
DOI : 10.3324/haematol.2009.006924

L. Castagna, R. Crocchiolo, S. Furst, S. Bramanti, E. Cheikh et al., Bone Marrow Compared with Peripheral Blood Stem Cells for Haploidentical Transplantation with a Nonmyeloablative Conditioning Regimen and Post-transplantation Cyclophosphamide, Biology of Blood and Marrow Transplantation, vol.20, issue.5, pp.724-733, 2014.
DOI : 10.1016/j.bbmt.2014.02.001

A. Bacigalupo, K. Ballen, D. Rizzo, S. Giralt, H. Lazarus et al., Defining the Intensity of Conditioning Regimens: Working Definitions, Biology of Blood and Marrow Transplantation, vol.15, issue.12, pp.1628-1661, 2009.
DOI : 10.1016/j.bbmt.2009.07.004

H. Shulman, K. Sullivan, P. Weiden, G. Mcdonald, G. Striker et al., Chronic graft-versus-host syndrome in man, The American Journal of Medicine, vol.69, issue.2, pp.204-221, 1980.
DOI : 10.1016/0002-9343(80)90380-0